GeneVentiv Therapeutics

GeneVentiv Therapeutics is a private, pre-clinical stage biotech founded in 2019, specializing in next-generation gene therapies for rare diseases. Its pipeline features two first-in-class candidates: GENV-HEM for hemophilia (including inhibitor patients) and GENV-002, a gene editing therapy for Pompe disease designed to offer lifelong enzyme production. The company is led by an experienced CEO and CSO and is supported by a world-class scientific advisory board with deep expertise in hemophilia and AAV gene therapy. GeneVentiv operates a capital-efficient, in-licensing and development business model and is currently pre-revenue.

Proprietary AAV viral vector delivery platform with a focus on minimizing host immune responses and enabling stable genomic integration for lifelong gene expression, including gene editing capabilities for Pompe disease.

In hemophilia, GeneVentiv faces competition from approved AAV gene therapies (e.g., BioMarin's Roctavian, CSL Behring's Hemgenix) and other pipeline candidates, necessitating a focus on durability and inhibitor patients. In Pompe, while gene therapy competition is earlier-stage, it must compete against established enzyme replacement therapy and other novel modalities in development.